
|Videos|May 6, 2011
Susan Moore on Adapting a Practice for Oral Oncolytics
Author(s)Susan Moore, RN, MSN
Susan Moore Oncology Nurse Practitioner/Consultant, MCG Oncology on Adapting a Practice for Use of Oral Oncolytics
Advertisement
Susan Moore, RN, MSN, ANP, AOCN®, Oncology Nurse Practitioner/Consultant, MCG Oncology, Chicago, IL on Adapting a Practice for Use of Oral Oncolytics
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
5




































